Ferrara L A, Strazzullo P, Scillitani A, Mancini M, Gagliardi R
Eur J Clin Pharmacol. 1985;28(3):241-4. doi: 10.1007/BF00543316.
Thiazide therapy is a widely used first line treatment for arterial hypertension. Its useful value, particularly in mild or moderate hypertension, is sometimes reduced by metabolic side-effects, as hypokalaemia and hyperuricaemia. In the present study the antihypertensive efficacy of a new, non-sulphonamide diuretic Bay g 2821 (muzolimine) was evaluated in comparison with the combination of hydrochlorothiazide-amiloride over a period of 4 weeks. A highly significant decrease in systolic and diastolic blood pressures was produced by both treatments. No decrease in serum potassium nor an increase in cholesterol, triglycerides, uric acid or glucose was detected during the 4 week treatment period. Subjective side-effects, such as headache and dizziness, were very rarely observed during Bay g 2821 treatment. The new diuretic appears, therefore, to be effective in the treatment of arterial hypertension without untoward side-effects.
噻嗪类疗法是治疗动脉高血压广泛使用的一线治疗方法。其有用价值，尤其是在轻度或中度高血压中，有时会因代谢副作用（如低钾血症和高尿酸血症）而降低。在本研究中，一种新型非磺胺类利尿剂Bay g 2821（莫唑胺）与氢氯噻嗪 - 阿米洛利联合用药相比，在4周的时间内评估了其降压疗效。两种治疗方法均使收缩压和舒张压显著降低。在4周的治疗期间未检测到血清钾降低，也未检测到胆固醇、甘油三酯、尿酸或葡萄糖升高。在Bay g 2821治疗期间很少观察到诸如头痛和头晕等主观副作用。因此，这种新型利尿剂似乎对治疗动脉高血压有效且无不良副作用。
